




At a
Glance 2022



Forward Thinking Healthcare

Fresenius is a **global healthcare group** offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 300,000 employees in more than 100 countries around the globe and annual sales exceeding €37 billion, Fresenius is one of the world's leading healthcare companies.

At Fresenius, the **patient always comes first**. For more than 100 years now we have been working to save lives and improve the quality of life of our patients. A clear **focus on innovation and efficiency** has helped us to make high-quality healthcare accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions. This is how Fresenius is contributing to **medical progress** and better patient care.

"Forward Thinking Healthcare" captures our commitment to the future: **better medicine for more people**.

Our year 2021



Staying fit and helping others

In October, employees worldwide lace up their jogging shoes for a donor run. Fresenius makes a donation on behalf of each participant - and helps more than 70 non-profit organizations.



Hospital network expanded

In September, Fresenius Helios acquires German Red Cross hospitals in the city of Kassel. In November, the company takes over an oncological center and an ophthalmic clinic in Medellin, Colombia.

Modern production

Fresenius Kabi continues to invest in the expansion and modernization of its production plants, including facilities in Austria, China and France.



Happy anniversary!

Fresenius Medical Care celebrates 25 years since its founding. The company marks the occasion with a €250,000 donation to help UNICEF combat the pandemic.

Growth strategy 2025

Fresenius Medical Care transforms its operating model into a simplified structure with just two business segments - to increase the transfer of knowledge and spur growth. The composition of the Management Board is adapted to the new operating model.



Fresenius vaccinates

Fresenius Helios administers more than 1 million COVID-19 vaccinations at around 150 facilities. Fresenius Medical Care makes dialysis centers available for vaccinations.






Products and services for individuals with renal diseases

Key Figures in € millions	2021	2020	Growth
Sales	17,619	17,859	2%
EBIT	1,915	2,499	-21%
Net income	1,018	1,359	-23%
Operating cash flow	2,489	4,233	-41%
Capital expenditure/ acquisitions	1,482	1,459	2%
R & D expenses	221	194	14%
Employees (Dec. 31)	130,251	133,129	-2%

Fresenius Medical Care is the world's largest provider of **products and services** for individuals with **renal diseases** of which more than 3.8 million patients worldwide regularly undergo dialysis treatment.

Through its network of more than 4,100 dialysis clinics, Fresenius Medical Care provides dialysis treatments for over 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines and dialyzers.


Along with its core business, the company offers a wide variety of other healthcare services and products.



IN 2021, FRESENIUS MEDICAL CARE PROVIDED
AROUND 53 MILLION DIALYSIS TREATMENTS
TO PATIENTS.

Products for critically and chronically ill patients

Key Figures in € millions	2021	2020	Growth
Sales	7,193	6,976	4%
EBIT	1,153	1,095	7%
Net income	778	730	8%
Operating cash flow	1,203	1,143	5%
Capital expenditure/ acquisitions	533	718	-26%
R & D expenses	595	553	8%
Employees (Dec. 31)	41,397	40,519	2%



**EVERY FOURTH BLOOD DONATION WORLDWIDE
IS COLLECTED IN A FRESENIUS KABI BLOOD BAG.**

Fresenius Kabi is a global healthcare company that specializes in **lifesaving medicines** and **technologies for infusion, transfusion and clinical nutrition**. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products.

In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.



Europe's leading private hospital operator

Key Figures <small>in € millions</small>	2021	2020	Growth
Sales	10,891	9,818	11%
EBIT	1,127	1,025	10%
Net income	728	666	10%
Operating cash flow	1,204	1,149	5%
Capital expenditure/ acquisitions	1,021	1,000	2%
R & D expenses	3	2	50%
Employees <small>(Dec. 31)</small>	123,484	116,952	6%

Fresenius Helios is Europe's **leading private hospital operator**, with more than 120,000 employees. Fresenius Helios includes Helios Kliniken in Germany, Quirónsalud in Spain and Latin America and the Eugin Group with a global network of reproductive clinics. Every year about 20 million patients choose Fresenius Helios for medical treatment.

Helios operates 89 acute care hospitals, about 130 outpatient clinics and six prevention centers in Germany. Quirónsalud operates 56 hospitals, including seven in Latin America, 88 outpatient centers and around 300 occupational risk prevention centers. Eugin Group's network comprises 33 clinics and an additional 39 sites across 10 countries on three continents.



**AROUND 87,000 BIRTHS TAKE PLACE IN
FRESENIUS HELIOS HOSPITALS ANNUALLY.**


Projects and services for healthcare facilities



Key Figures in € millions	2021	2020	Growth
Sales	2,297	2,068	11%
EBIT	101	29	--
Net income	67	2	--
Operating cash flow	151	78	94%
Capital expenditure/ acquisitions	81	101	-20%
Order intake	1,290	1,010	28%
Employees (Dec. 31)	19,721	19,414	2%

Fresenius Vamed is a leading global provider of **services for hospitals** and other **healthcare facilities**. Its portfolio ranges from project development, planning and turnkey construction through to total operational management of healthcare facilities and providing services to patients. The services are aimed at various areas of healthcare, ranging from prevention to acute care, rehabilitation, and nursing.

Headquartered in Vienna, Austria, Fresenius Vamed has successfully completed more than 1,000 healthcare projects in 98 countries on five continents since the company's founding in 1982.



**FRESENIUS VAMED IS THE LEADING PRIVATE
REHABILITATION CARE PROVIDER IN AUSTRIA,
THE CZECH REPUBLIC, GERMANY AND
SWITZERLAND, WITH MORE THAN 8,200 BEDS.**

■ Employees
As of: December 2021



■ Sales
in 2021



316,078

€ 37.5 billion

24% ■ 38%
North America

Dialysis clinics: 2,683
Production sites: 13

Fresenius
Group Headquarters
Bad Homburg
Germany

57% ■ 45%
Europe

Dialysis clinics: 707
Hospitals: 138
Production sites: 47

10% ■ 6%
**Latin America
and Africa**

Dialysis clinics: 333
Hospitals: 7
Production sites: 16

9% ■ 11%
Asia Pacific

Dialysis clinics: 448
Production sites: 19

Total:



Dialysis clinics: 4,171




Hospitals: 145



Production sites: 95


Sustainability



* Scope 1 and 2

A commitment to operating responsibly and sustainably is part of our company's business culture, and of the way we work every day. Living up to our legal and ethical responsibilities as a globally active company is important to us.

We therefore adjusted our Management Board compensation system in 2021. In addition to key financial indicators, it now takes into account sustainability targets relating to environmental, social and governance aspects. For this purpose, we have identified the following topic areas:



In managing these topic areas, we will also use key performance indicators such as patient satisfaction, medical treatment quality, diversity, and innovation. The Management Board approved these performance indicators last year. They will be compiled and regularly measured starting in 2022.



From a local pharmacy to a global corporation

1462

Opening of the Hirsch Pharmacy in Frankfurt

In the 19th century, ownership of the pharmacy passes to the Fresenius family.

1912

Founding of the company

The pharmacist Dr. Eduard Fresenius, proprietor of the Hirsch Pharmacy, establishes the pharmaceutical company Dr. E. Fresenius.

1946

Founder **Eduard Fresenius dies**



1966

Distributor of dialysis machines

Fresenius starts to sell dialysis machines and dialyzers manufactured by various non-German companies.

1979

Development and sale of company's own dialysis machines

Production of the A2008 dialysis machine begins in a newly acquired factory in Schweinfurt, Germany.

1994

Entry into project business

With the acquisition of Hospitalia International, Fresenius enters the project business to develop hospitals and other healthcare facilities.

1986

Fresenius listed on stock market

1952

Else Kröner assumes management of Fresenius

The foster daughter of Eduard Fresenius will, along with her future husband Hans Kröner, build the company into a global healthcare group over the following decades.



1996

Entry into Dialysis Services

Fresenius Medical Care is created when the U.S. dialysis provider National Medical Care, acquired by Fresenius, is merged with Fresenius' own dialysis business. The project business is expanded with the acquisition of VAMED AG.



1999

Expansion of infusions business

The nutrition business of Pharmacia & Upjohn is acquired and then merged with Fresenius Pharma to form Fresenius Kabi.



2005

Expansion of hospital business

Fresenius acquires Helios, one of Germany's leading private hospital operators.

2017

Hospital network expanded outside of Germany

Fresenius Helios acquires Quirónsalud, Spain's largest private hospital operator.

2021

Entry into reproductive medicine

Fresenius Helios takes over the Eugin Group, a leading international group in the field of fertility treatments.

2008

Expansion in I.V. generics

Fresenius Kabi enters the North American pharmaceuticals market through the acquisition of APP Pharmaceuticals.

2022

Active around the world

With more than 300,000 employees in over 100 countries, Fresenius is one of the world's leading healthcare companies.





Financial Calendar 2022

Publication of 2021 business results	February 22, 2022
Results 1 st Quarter	May 4, 2022
Annual General Meeting (virtual)	May 13, 2022
Results 2 nd Quarter	August 2, 2022
Results 3 rd Quarter	November 1, 2022

More information is available online:
atagance.fresenius

Fresenius SE & Co. KGaA

Else-Kröner-Str. 1
61352 Bad Homburg
Germany

T +49 6172 608-0
www.fresenius.com


Contact for Media

Corporate Communications
T +49 6172 608-2501
pr-fre@fresenius.com

Contact for Shareholders

Investor Relations
T +49 6172 608-2487
ir-fre@fresenius.com

Contact for Job Applicants

Employer Branding
 +49 172 7407809
careers@fresenius.com



www.fresenius.com/socialmedia

More information:
ataglance.fresenius



Some figures adjusted for special items; when applicable, changes are in constant currency. Net income = Net income attributable to the parent company of the respective business segment.

